I-Mab - ADR
IMAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$235.29M
Close$
$0.12
96% downside
Current Fair Value
96% downsideOvervalued by 96% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $235.29 Million |
|---|---|
| Enterprise Value | $73.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.62 |
| Beta | 1.46 |
| Outstanding Shares | 81,699,277 |
Return
| Return on Equity | -19.42% |
|---|---|
| Return on Assets | -18.48% |
| Return on Invested Capital | -18.50% |
Valuation & Multiples
| P/E Ratio | -2.44 |
|---|---|
| PEG | 2 |
| Price to Sales | - |
| Price to Book Ratio | 1.44 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.99 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 1, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8203▲ 12.83% |
|---|---|
| Total Calls | 21,700▼ 13.20% |
| Total Puts | 39,500▼ 6.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 40.64%▲ 4.30% |
|---|---|
| Total Invested | $132.14M▲ 17.66% |
| Investors Holding | 61▲ 16.00% |
ESG Score
No data
About I-Mab
30 employees
CEO: Srishti Gupta NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a b...